Get started
Author

Alexia Richard

Observed names: A Richard, Richard A
Observed institution: Novartis (Switzerland)
OpenAlex ID: A5111019430
Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes
2012 · Hans-Henrik Parving, Barry M. Brenner, et al. · New England Journal of Medicine · 1,319
PDF
Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE)
2012 · Hans-Henrik Parving, Barry M Brenner, et al. · Journal of the Renin-Angiotensin-Aldosterone System · 61
Once-daily mometasone plus indacaterol versus mometasone or twice-daily fluticasone plus salmeterol in patients with inadequately controlled asthma (PALLADIUM): a randomised, double-blind, triple-dummy, controlled phase 3 study
2020 · Richard N van Zyl-Smit, Matthias Krüll, et al. · The Lancet Respiratory Medicine · 49
Efficacy and safety of omalizumab in Chinese patients with anti‐histamine refractory chronic spontaneous urticaria
2022 · Weiru Yuan, Shuling Hu, et al. · Dermatologic Therapy · 36
Indacaterol acetate/mometasone furoate provides sustained improvements in lung function compared with salmeterol xinafoate/fluticasone propionate in patients with moderate-to-very-severe COPD: results from a Phase II randomized, double-blind 12-week study
2018 · Kai Michael Beeh, Anne-Marie Kirsten, et al. · International Journal of COPD · 11
PDF
Effect of indacaterol/mometasone on lung function in adolescents versus overall patient population: PALLADIUM study
2020 · Matthias Krüll, Richard Van Zyl-Smit, et al. · European Respiratory Journal
P224 Efficacy and long-term safety of QMF149 (indacaterol acetate/mometasone furoate) versus mometasone furoate and versus salmeterol xinafoate/fluticasone propionate in patients with inadequately-controlled asthma: The PALLADIUM study
2019 · R van Zyl-Smit, M Krull, et al. · Thorax
Indacaterol acetate/mometasone furoate provides sustained improvements in lung function compared with salmeterol xinafoate/fluticasone propionate in patients with moderate-to-very-severe COPD: results from a Phase II randomized, double-blind 12-week study
2018 · Beeh KM, Kirsten AM, et al. · DOAJ (DOAJ: Directory of Open Access Journals)
Works count: 8
Citation count: 1,476
H-index: 5
I10-index: 5
Year
Topic
Type